Cargando…
Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
BACKGROUND: Structure-based drug design (SBDD) can provide valuable guidance to drug discovery programs. Robust construct design and expression, protein purification and characterization, protein crystallization, and high-resolution diffraction are all needed for rapid, iterative inhibitor design. W...
Autores principales: | Argiriadi, Maria A, Sousa, Silvino, Banach, David, Marcotte, Douglas, Xiang, Tao, Tomlinson, Medha J, Demers, Megan, Harris, Christopher, Kwak, Silvia, Hardman, Jennifer, Pietras, Margaret, Quinn, Lisa, DiMauro, Jennifer, Ni, Baofu, Mankovich, John, Borhani, David W, Talanian, Robert V, Sadhukhan, Ramkrishna |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678131/ https://www.ncbi.nlm.nih.gov/pubmed/19296855 http://dx.doi.org/10.1186/1472-6807-9-16 |
Ejemplares similares
-
Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
por: Argiriadi, Maria A, et al.
Publicado: (2012) -
CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches
por: Argiriadi, Maria A., et al.
Publicado: (2019) -
Twitchin kinase interacts with MAPKAP kinase 2 in Caenorhabditis elegans striated muscle
por: Matsunaga, Yohei, et al.
Publicado: (2015) -
Phosphorylation of the RNA-binding protein Dazl by MAPKAP kinase 2 regulates spermatogenesis
por: Williams, Patrick A., et al.
Publicado: (2016) -
The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor
por: Kostenko, Sergiy, et al.
Publicado: (2010)